Effect of TP53 Rs1042522 on the Susceptibility of Patients to Oral Squamous Cell Carcinoma and Oral Leukoplakia: a Meta-analysis

Overview

Journal BMC Oral Health

Publisher Biomed Central

Specialty Dentistry

Date 2018 Aug 22

PMID 30126398

Citations 2

Authors

Zhen Sun

Wei Gao

Jiang-Tao Cui

Affiliations

Soon will be listed here.

Abstract

Background: There are different and inconsistent conclusions regarding the genetic relationship between the human tumor suppressor p53 (TP53) rs1042522 polymorphism and the risk of oral squamous cell carcinoma (OSCC) and oral leukoplakia (OL). Therefore, the aim of the study was to comprehensively reassess this association through the performance of an updated meta-analysis.

Methods: After searching the available databases, we systematically screened and included the eligible case-control studies, which contain the full genotype frequency data of the TP53 rs1042522 polymorphism for both OSCC/OL patients and the negative control groups. P (P-value of the association test) and ORs (odd ratios) with their corresponding 95% CIs (confidence intervals) were calculated to quantitatively evaluate the influence of TP53 rs1042522 on the susceptibility of patients to OSCC or OL.

Results: In total, twenty eligible case-control articles were finally enrolled. Compared with the controls, no increased or decreased risk of OSCC was observed in the cases for six genetic models including allele C vs. G (P = 0.741), carrier C vs. G (P = 0.853), homozygote CC vs. GG (P = 0.085), heterozygote GC vs. GG (P = 0.882), dominant GC + CC vs. GG (P = 0.969), and recessive CC vs. GG + GC (P = 0.980). Furthermore, no statistically significant difference between the cases and controls was detected in most subgroup meta-analyses (P > 0.05). For the risk of OL, we did not observe the difference between the cases and controls for most genetic models in the overall meta-analysis and subsequent subgroup analysis (P > 0.05). Begg's test and Egger's test excluded the large risk of publication bias within the included studies in the meta-analysis of OSCC. The sensitivity analysis indicated the above relatively stable results.

Conclusions: Our updated meta-analysis (based on the current evidence) shows that TP53 rs1042522 may not confer susceptibility to OSCC. In addition, for the first time, we provided evidence regarding the negative association between TP53 rs1042522 and OL risk.

Citing Articles

Systematic evaluation of TP53 codon 72 polymorphism associated with onset and progression of oral potentially malignant disorders.

Li H, Liu Y, Zhou S, Zhou Q, Yang X BMC Oral Health. 2023; 23(1):659.

PMID: 37697274 PMC: 10496165. DOI: 10.1186/s12903-023-03316-0.

Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews.

Gonzalez-Moles M, Warnakulasuriya S, Lopez-Ansio M, Ramos-Garcia P Cancers (Basel). 2022; 14(15).

PMID: 35954497 PMC: 9367256. DOI: 10.3390/cancers14153834.

References

Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F . Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998; 393(6682):229-34. DOI: 10.1038/30400. View

Isobe M, Emanuel B, Givol D, Oren M, Croce C . Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986; 320(6057):84-5. DOI: 10.1038/320084a0. View

Tian X, Dai S, Sun J, Jiang S, Jiang Y . The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies. Oncotarget. 2016; 8(1):1156-1165. PMC: 5352043. DOI: 10.18632/oncotarget.13589. View

Yan Y, Wu R, Li S, He J . Meta-analysis of association between the TP53 Arg72Pro polymorphism and risk of endometriosis based on case-control studies. Eur J Obstet Gynecol Reprod Biol. 2015; 189:1-7. DOI: 10.1016/j.ejogrb.2015.03.015. View

Jing G, Lv K, Jiao X . The p53 codon 72 polymorphism and the risk of oral cancer in a Chinese Han population. Genet Test Mol Biomarkers. 2012; 16(9):1149-52. DOI: 10.1089/gtmb.2012.0138. View

Zarate A, Don J, Secchi D, Carrica A, Galindez Costa F, Panico R . Study of the TP53 codon 72 polymorphism in oral cancer and oral potentially malignant disorders in Argentine patients. Tumour Biol. 2017; 39(5):1010428317699113. DOI: 10.1177/1010428317699113. View

Zemleduch T, Lianeri M, Rydzanicz M, Gajecka M, Szyfter K, Jagodzinski P . Contribution of polymorphism in codon 72 of TP53 gene to laryngeal cancer in Polish patients. Oral Oncol. 2008; 45(8):683-6. DOI: 10.1016/j.oraloncology.2008.10.009. View

Lin Y, Huang H, Wang L, Tsai C, Lung O, Dai C . Polymorphisms of COX-2 -765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008; 44(8):798-804. DOI: 10.1016/j.oraloncology.2007.10.006. View

Ramya A, Majumdar S, Babu T, Uppala D, Srinivas B, Rao A . Expression of Human Papillomavirus DNA and p53 Polymorphisms through Polymerase Chain Reaction in Normal Mucosa and Oral Leukoplakia Individuals with Deleterious Oral Habits. Int J Appl Basic Med Res. 2017; 7(2):134-138. PMC: 5441263. DOI: 10.4103/ijabmr.IJABMR_57_16. View

10.

Hanel W, Moll U . Links between mutant p53 and genomic instability. J Cell Biochem. 2011; 113(2):433-9. PMC: 4407809. DOI: 10.1002/jcb.23400. View

11.

Wang Z, Sturgis E, Zhang Y, Huang Z, Zhou Q, Wei Q . Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int J Cancer. 2011; 131(3):E251-8. PMC: 3289741. DOI: 10.1002/ijc.27335. View

12.

Drummond S, De Marco L, Pordeus I, Barbosa A, Gomez R . TP53 codon 72 polymorphism in oral squamous cell carcinoma. Anticancer Res. 2003; 22(6A):3379-81. View

13.

Kitkumthorn N, Yanatatsaneejit P, Rabalert J, Dhammawipark C, Mutirangura A . Association of P53 codon 72 polymorphism and ameloblastoma. Oral Dis. 2010; 16(7):631-5. DOI: 10.1111/j.1601-0825.2010.01664.x. View

14.

Perrone F, Mariani L, Pastore E, Orsenigo M, Suardi S, Marcomini B . p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. Cancer. 2007; 109(12):2461-5. DOI: 10.1002/cncr.22702. View

15.

Ji X, Neumann A, Sturgis E, Adler-Storthz K, Dahlstrom K, Schiller J . p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis. 2008; 29(4):875-9. DOI: 10.1093/carcin/bgn039. View

16.

Nagpal J, Patnaik S, Das B . Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer. 2002; 97(5):649-53. DOI: 10.1002/ijc.10112. View

17.

Ihsan R, Devi T, Yadav D, Mishra A, Sharma J, Zomawia E . Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol. 2010; 30(3):163-71. DOI: 10.1089/dna.2010.1119. View

18.

Tandle A, Sanghvi V, Saranath D . Determination of p53 genotypes in oral cancer patients from India. Br J Cancer. 2001; 84(6):739-42. PMC: 2363816. DOI: 10.1054/bjoc.2000.1674. View

19.

Kuroda Y, Nakao H, Ikemura K, Katoh T . Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. Oral Oncol. 2007; 43(10):1043-8. DOI: 10.1016/j.oraloncology.2006.12.001. View

20.

Yu C, Lin H, Cheng S, Sun A, Chen H . Cryotherapy for oral precancers and cancers. J Formos Med Assoc. 2014; 113(5):272-7. DOI: 10.1016/j.jfma.2014.01.014. View